UNSPSC 51401530: Girisopam

This classification denotes an anxiolytic with the molecular formula C18H17ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LP301A921, chemically known as 5h-2,3-benzodiazepine, 1-(3-chlorophenyl)-7,8-dimethoxy-4-methyl- but generally known as girisopam, which bears US NIH Compound Identifier 71257. European Medicines Agency schedules Girisopam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07907MIG.

UNSPSC 51401530 Girisopam, a Commodity code, covers pharmaceutical products — naloxone, generic multi-source pharmaceuticals, over-the-counter medications, and related drug-delivery systems — that state and local government health agencies, cooperative purchasing alliances, and community health departments procure for public health initiatives, emergency response, and ongoing pharmacy benefit programs. State and local buyers under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations serving participating state and local facilities. The scope of work ranges from direct product purchase and distribution contracts to strategic pharmacy benefit management initiatives, with vendors typically required to demonstrate FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and ability to work through established pharmaceutical wholesalers and supply chains.

Recent activity shows concentrated procurement across Florida and Minnesota through multiple issuing bodies and notice types. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, under a two-year initial term with one-year renewal option; bidders must include shipping and delivery costs and comply with E-Verify and drug-free workplace requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with products effective July 1, 2026, requiring vendors to work through three authorized wholesalers and meet cGMP and DSCSA compliance standards. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a statewide Therapeutic Pharmacy Initiative, representing early-stage strategic procurement planning rather than immediate competitive bidding.